Zobrazeno 1 - 9
of 9
pro vyhledávání: '"David P Hudesman"'
Autor:
Simon J. Hong, Sumona Bhattacharya, Aiya Aboubakr, Devika Nadkarni, Diana Lech, Ryan C. Ungaro, Manasi Agrawal, Robert P. Hirten, Ruby Greywoode, Anjali Mone, Shannon Chang, David P. Hudesman, Thomas Ullman, Keith Sultan, Dana J. Lukin, Jean-Frederic Colombel, Jordan E. Axelrad
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disea
Externí odkaz:
https://doaj.org/article/c495159386a24a36ab769d8b7bf50509
Autor:
David P. Hudesman, Soumya D. Chakravarty, Bruno Emond, Lorie A. Ellis, Patrick Lefebvre, Kay Sadik, Jose U. Scher
Publikováno v:
BMC Rheumatology, Vol 4, Iss 1, Pp 1-13 (2020)
Abstract Background Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis) are associa
Externí odkaz:
https://doaj.org/article/bcbb661d25e443bba9217df50f4dcc9c
Autor:
David P. Hudesman, Joana Torres, Leonardo Salese, John C. Woolcott, Rajiv Mundayat, Chinyu Su, Mahmoud H. Mosli, Jessica R. Allegretti
Publikováno v:
The Patient - Patient-Centered Outcomes Research. 16:95-103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c32ca21e40f7824c4ee2a2ae6efd46d3
https://doi.org/10.1007/s40271-022-00603-w
https://doi.org/10.1007/s40271-022-00603-w
Autor:
Rebecca H, Haberman, Seungha, Um, Jordan E, Axelrad, Rebecca B, Blank, Zakwan, Uddin, Sydney, Catron, Andrea L, Neimann, Mark J, Mulligan, Ramin Sedaghat, Herat, Simon J, Hong, Shannon, Chang, Arnold, Myrtaj, Ghoncheh, Ghiasian, Peter M, Izmirly, Amit, Saxena, Gary, Solomon, Natalie, Azar, Jonathan, Samuels, Brian D, Golden, Paula, Rackoff, Samrachana, Adhikari, David P, Hudesman, Jose U, Scher
Publikováno v:
The Lancet Rheumatology. 4:e384-e387
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83b3b61db514ff503b5ff1c5dd331d7d
https://doi.org/10.1016/s2665-9913(22)00069-8
https://doi.org/10.1016/s2665-9913(22)00069-8
Autor:
Jordan E Axelrad, Terry Li, Salam P Bachour, Takahiro I Nakamura, Ravi Shah, Michael C Sachs, Shannon Chang, David P Hudesman, Stefan D Holubar, Amy L Lightner, Edward L Barnes, Benjamin L Cohen, Florian Rieder, Eren Esen, Feza Remzi, Miguel Regueiro, Benjamin Click
Publikováno v:
Inflammatory bowel diseases.
Background Postoperative recurrence (POR) of Crohn’s disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). Methods We performed a retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23fd0bc9aa056846e18141e74ade3390
https://pubmed.ncbi.nlm.nih.gov/35905032
https://pubmed.ncbi.nlm.nih.gov/35905032
Publikováno v:
The Journal of Rheumatology. :jrheum.221196
In individuals with inflammatory bowel disease (IBD), extraintestinal manifestations (EIMs) represent a significant burden of illness, with reported prevalence rates of up to 50%.1Of the various types of EIMs, the most commonly involved organ system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::234b2beefb63a34302d32e458ac46189
https://doi.org/10.3899/jrheum.221196
https://doi.org/10.3899/jrheum.221196
Autor:
Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro
Publikováno v:
Inflammatory bowel diseases. 29(1)
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). These post hoc analyses assessed associations between C-reactive protein (CRP), partial Mayo score (PMS), and efficacy outcomes during tofac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f095cb872f56735ba8ca746205ec52ea
https://pubmed.ncbi.nlm.nih.gov/35380664
https://pubmed.ncbi.nlm.nih.gov/35380664
Autor:
Simon J Hong, Cameron Zenger, Jillian Pecoriello, Alice Pang, Margaret Vallely, David P Hudesman, Shannon Chang, Jordan E Axelrad
Publikováno v:
Inflamm Bowel Dis
Background There is little data regarding the risk of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a prior history of cancer who are exposed to ustekinumab or vedolizumab. We assessed the risk of subsequent cancer in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::244781ea42a24111fb40b9141d44f886
https://pubmed.ncbi.nlm.nih.gov/35262671
https://pubmed.ncbi.nlm.nih.gov/35262671
Autor:
Simon J, Hong, Janice, Jang, Dana, Berg, Tarik, Kirat, Feza, Remzi, Shannon, Chang, Lisa B, Malter, Jordan E, Axelrad, David P, Hudesman
Publikováno v:
Digestive diseases and sciences. 66(11)
There is wide variation in the quality of care of hospitalized patients with inflammatory bowel disease (IBD). Prior studies have demonstrated that a specialized inpatient IBD service improves short-term outcomes. In this study, we assessed the impac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6439307e2bc7889ca4a63e805be7da50
https://pubmed.ncbi.nlm.nih.gov/33474649
https://pubmed.ncbi.nlm.nih.gov/33474649